Injecting nivolumab (Opdivo) directly into precancerous oral lesions led to a reduction in lesion size and allowed some patients to avoid surgery, according to research from a Phase I clinical trial presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17–22.
This article was originally published on MedicalXpress.com

